公开(公告)号：US09493834B2

公开(公告)日：2016-11-15

申请号：US13387174

申请日：2010-07-29

Applicant: Daniel Cohen ,  Ilya Chumakov ,  Serguei Nabirochkin ,  Oxana Guerassimenko ,  Esther Graudens

Inventor： Daniel Cohen ,  Ilya Chumakov ,  Serguei Nabirochkin ,  Oxana Guerassimenko ,  Esther Graudens

IPC: G01N33/53 ,  C12Q1/68 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/6896 ,  G01N2800/2821 ,  G01N2800/60

Abstract: The present invention relates to development, validation and application of new sets of biomarkers for diagnosis of Alzheimer's disease (AD) and related disorders including early diagnosis of MCI and early prodrome of AD, identification of disease sub types, prediction of their response to disease management procedures, drugs and their combinations and for monitoring response for these treatments, including validation of biomarkers for clinical trials.

Abstract translation: 本发明涉及用于诊断阿尔茨海默病（AD）的新型生物标志物的发展，验证和应用以及相关疾病，包括MCI的早期诊断和AD的早期前驱症，疾病亚型的鉴定，对疾病管理的反应的预测 程序，药物及其组合，并监测这些治疗的反应，包括验证临床试验的生物标志物。

公开(公告)号：US08992891B2

公开(公告)日：2015-03-31

申请号：US12744962

申请日：2008-11-28

Applicant: Daniel Cohen ,  Ilya Chumakov ,  Oxana Guerassimenko ,  Serguei Nabirochkin

Inventor： Daniel Cohen ,  Ilya Chumakov ,  Oxana Guerassimenko ,  Serguei Nabirochkin

IPC: A61K31/197 ,  A61K31/4164 ,  A61K39/395 ,  A61K31/485 ,  A61K9/127 ,  A61K9/00 ,  A61K9/08 ,  A61K9/48 ,  A61K31/7004

CPC classification number: A61K31/485 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/4866 ,  A61K31/047 ,  A61K31/197 ,  A61K31/7004

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject.

Abstract translation: 本发明涉及治疗Charcot-Marie-Tooth疾病和相关疾病的组合物和方法。 更具体地，本发明涉及通过影响受试者中的PMP22表达来治疗所述疾病的组合疗法。

公开(公告)号：US08716269B2

公开(公告)日：2014-05-06

申请号：US12999125

申请日：2009-06-17

Applicant: Daniel Cohen ,  Ilya Chumakov ,  Serguei Nabirochkin ,  Oxana Guerassimenko

Inventor： Daniel Cohen ,  Ilya Chumakov ,  Serguei Nabirochkin ,  Oxana Guerassimenko

IPC: A61K31/56 ,  A61K31/4164 ,  A61P25/00 ,  A61K31/4178

CPC classification number: A61K31/047 ,  A61K31/192 ,  A61K31/197 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/436 ,  A61K31/439 ,  A61K31/485 ,  A61K31/575 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.

Abstract translation: 本发明涉及治疗Charcot-Marie-Tooth病和相关周围神经病的组合物和方法。 更具体地，本发明涉及通过同时影响受试者中毒蕈碱受体信号传导和甲状腺激素途径来治疗所述疾病的组合疗法。

公开(公告)号：US20120088744A1

公开(公告)日：2012-04-12

申请号：US13375288

申请日：2010-05-28

Applicant: Daniel Cohen ,  Serguei Nabirochkin ,  Ilya Chumakov

Inventor： Daniel Cohen ,  Serguei Nabirochkin ,  Ilya Chumakov

IPC: A61K31/567 ,  A61K31/439 ,  A61K31/436 ,  A61K31/4164 ,  A61P25/00 ,  A61P21/00 ,  A61K31/4178 ,  A61K31/192 ,  B82Y5/00

CPC classification number: A61K31/485 ,  A61K9/0053 ,  A61K31/047 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/436 ,  A61K31/439 ,  A61K31/555 ,  A61K31/567 ,  A61K31/575 ,  A61K31/7004 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract translation: 本发明涉及治疗Charcot-Marie-Tooth疾病和相关疾病的组合物和方法。

公开(公告)号：US20100234236A1

公开(公告)日：2010-09-16

申请号：US12744363

申请日：2008-11-28

Applicant: Daniel Cohen ,  Ilya Chumakov

Inventor： Daniel Cohen ,  Ilya Chumakov

IPC: C40B30/02

CPC classification number: G16H50/50 ,  G06F19/00 ,  G06F19/18 ,  G06F19/326 ,  G06F19/3456 ,  Y02A90/26

Abstract: The present invention relates to methods for drug repositioning. More particularly, this invention relates to methods for selecting approved drugs or combinations of approved drugs for use in new therapeutic indications. This approach is situated in a cross section between drug repositioning and disease treatment by combinations of drugs with additive or synergistic action. The invention also allows to define drugs or drug combinations for treating the unmet medical need in diseases neglected by majority of Pharma companies, such as orphan diseases.

Abstract translation: 本发明涉及药物重新定位的方法。 更具体地，本发明涉及用于选择用于新的治疗适应症的批准药物或批准药物的组合的方法。 该方法位于药物重新定位和疾病治疗之间的横截面，其中药物与添加剂或协同作用的组合。 本发明还允许定义药物或药物组合来治疗大多数Pharma公司忽视的疾病，例如孤儿疾病。

公开(公告)号：US20080184381A1

公开(公告)日：2008-07-31

申请号：US12050492

申请日：2008-03-18

Applicant: Daniel Cohen ,  Ilya Chumakov ,  Anne-Marie Simon ,  Hadi Abderrahim

Inventor： Daniel Cohen ,  Ilya Chumakov ,  Anne-Marie Simon ,  Hadi Abderrahim

IPC: A01K67/00 ,  C07H21/04 ,  C40B40/08 ,  C12P21/04 ,  G01N33/53 ,  C12Q1/68 ,  C07K16/00 ,  C12N15/00

CPC classification number: C07K14/705 ,  A01K2217/05

Abstract: The invention concerns the genomic DNA, cDNA, and polypeptide sequences of CanIon, a novel voltage gated ion channel protein. The invention also concerns biallelic markers of the CanIon gene. The CanIon gene may be used as a biological target for the treatment and diagnosis of schizophrenia, bipolar disorder, and other diseases and conditions.

Abstract translation: 本发明涉及CanIon（一种新型电压门控离子通道蛋白）的基因组DNA，cDNA和多肽序列。 本发明还涉及CanIon基因的双重标记。 CanIon基因可以用作治疗和诊断精神分裂症，双相性精神障碍和其他疾病和病症的生物靶标。

公开(公告)号：US07402393B2

公开(公告)日：2008-07-22

申请号：US10491772

申请日：2002-10-03

Applicant: Ilya Chumakov ,  Oxana Guerassimenko

Inventor： Ilya Chumakov ,  Oxana Guerassimenko

IPC: G01N33/53

CPC classification number: C07K14/47 ,  A61K9/0053 ,  A61K9/0073 ,  A61K9/4808 ,  A61K38/00 ,  A61K48/00

Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GZIP polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Abstract translation: 本发明涉及代谢研究领域。 代谢紊乱，如肥胖，是一个严重而广泛的公共卫生问题。 已经鉴定出被认为对治疗代谢紊乱有益的GZIP多肽。 这些化合物应该有效减少体重和治疗与代谢有关的疾病和病症。 这些代谢相关的疾病和病症包括高脂血症，动脉粥样硬化，糖尿病和高血压。

公开(公告)号：US20070087983A1

公开(公告)日：2007-04-19

申请号：US10570121

申请日：2004-09-02

Applicant: Ilya Chumakov ,  Oxana Guerassimenko

Inventor： Ilya Chumakov ,  Oxana Guerassimenko

IPC: G01N33/53 ,  A61K31/711 ,  C12Q1/68 ,  C07H21/04 ,  C12N9/64 ,  A61K48/00 ,  C12P21/06

CPC classification number: C07K14/47 ,  C12N9/6421 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/566 ,  G01N33/6893 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/122 ,  G01N2800/205

Abstract: The invention encompasses a novel gene encoding a protein of the ubiquitin-proteasome pathway, UBP8rp. The invention also relates the use of UBP8rp polypeptides for screening for modulators, and to the use of said modulators for treating chronic inflammatory diseases such as, e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease and multiple sclerosis. The invention further relates to the use of biallelic markers located in the UBP8rp gene for diagnosing said chronic inflammatory diseases.

Abstract translation: 本发明包括编码泛素 - 蛋白酶体途径UBP8rp的蛋白质的新基因。 本发明还涉及UBP8rp多肽用于筛选调节剂的用途，以及所述调节剂用于治疗慢性炎性疾病如牛皮癣，银屑病关节炎，类风湿性关节炎，哮喘，炎症性肠病和多发性硬化症的用途。 本发明还涉及位于UBP8rp基因中的用于诊断所述慢性炎症性疾病的双重标记物的用途。

公开(公告)号：US07067627B2

公开(公告)日：2006-06-27

申请号：US10147603

申请日：2002-05-16

Applicant: Daniel Cohen ,  Marta Blumenfeld ,  Ilya Chumakov ,  Lydie Bougueleret ,  Bernard Bihain ,  Laurent Essioux

Inventor： Daniel Cohen ,  Marta Blumenfeld ,  Ilya Chumakov ,  Lydie Bougueleret ,  Bernard Bihain ,  Laurent Essioux

IPC: C07K1/00 ,  A23J1/00

CPC classification number: C12Q1/6883 ,  A01K2217/075 ,  C07K14/47 ,  C12Q2600/156

Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

公开(公告)号：US07041454B2

公开(公告)日：2006-05-09

申请号：US10376893

申请日：2003-02-27

Applicant: Marta Blumenfeld ,  Ilya Chumakov ,  Lydie Bougueleret ,  Annick Cohen-Akenine

Inventor： Marta Blumenfeld ,  Ilya Chumakov ,  Lydie Bougueleret ,  Annick Cohen-Akenine

IPC: C07H21/04 ,  C12Q1/68

CPC classification number: C12N9/10 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  A61K48/00 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N2500/10

Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.